129 active
/
351 total (since 2015)
56
Phase 1 Active
119 total
64
Phase 2 Active
158 total
35
Phase 3 Active
96 total
11
Phase 4 Active
40 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Roche 9 7 3
AbbVie 6 6 0
Chengdu Origen Biotechnology Co., Ltd. 4 0 0
EyeBiotech Ltd. 3 1 0
4D Molecular Therapeutics 3 0 0
Innostellar Biotherapeutics Co.,Ltd 3 0 0
Novartis 2 19 3
Regeneron 2 3 1
EyePoint Pharmaceuticals, Inc. 2 2 0
Ocular Therapeutix, Inc. 2 2 0
Adverum Biotechnologies, Inc. 2 1 0
Alkeus Pharmaceuticals, Inc. 2 1 0
Perceive Biotherapeutics, Inc. 2 0 0
Exegenesis Bio 2 0 0
Beijing Anlong Biopharmaceutical Co., Ltd. 2 0 0
NCT07007065 RECRUITING
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie n=561
NCT06668064 ACTIVE NOT RECRUITING
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals, Inc. n=400
NCT06683742 ACTIVE NOT RECRUITING
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals, Inc. n=400
NCT06847542 RECRUITING
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Hoffmann-La Roche n=250
NCT06541704 RECRUITING
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals n=975
NCT03683251 RECRUITING
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Hoffmann-La Roche n=1,000
NCT07440225 NOT YET RECRUITING
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd. n=960
NCT04704921 RECRUITING
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie n=630
NCT07064759 RECRUITING
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics n=480
NCT04657289 ACTIVE NOT RECRUITING
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Hoffmann-La Roche n=451
NCT04663750 RECRUITING
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
King's College Hospital NHS Trust n=210
NCT05562947 RECRUITING
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche n=68
NCT05904028 RECRUITING
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Jaeb Center for Health Research n=600
NCT06864988 RECRUITING
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics n=480
NCT07317934 NOT YET RECRUITING
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Innostellar Biotherapeutics Co.,Ltd n=332
NCT07269769 NOT YET RECRUITING
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
Tasly Pharmaceutical Group Co., Ltd n=450
NCT06952452 RECRUITING
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
Parc de Salut Mar n=630
NCT06856577 RECRUITING
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Adverum Biotechnologies, Inc. n=284
NCT06373731 ACTIVE NOT RECRUITING
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. n=313
NCT06556368 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Kodiak Sciences Inc n=675
NCT06491914 ACTIVE NOT RECRUITING
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals n=1,118
NCT05407636 RECRUITING
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
AbbVie n=660
NCT07189169 RECRUITING
QA108 Phase III Study in Subjects With Intermediate AMD
Smilebiotek Zhuhai Limited n=400
NCT07129239 NOT YET RECRUITING
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
Clinique de Retine de l'est n=180
NCT06495918 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Ocular Therapeutix, Inc. n=825
NCT06305416 RECRUITING
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Incepta Pharmaceuticals Ltd n=70
NCT06223958 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. n=344
NCT06470373 NOT YET RECRUITING
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
Rophibio, Inc. n=434
NCT05972473 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
Innovent Biologics (Suzhou) Co. Ltd. n=600
NCT05461339 ACTIVE NOT RECRUITING
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd. n=488
NCT06572553 RECRUITING
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University n=30
NCT06229665 ACTIVE NOT RECRUITING
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
LumiThera, Inc. n=75
NCT05112861 ACTIVE NOT RECRUITING
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=120
NCT06165068 RECRUITING
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
Navamindradhiraj University n=174
NCT05251636 NOT YET RECRUITING
Adjunct Episcleral Brachytherapy for PCV
Salutaris Medical Devices, Inc. n=159
NCT07389577 COMPLETED
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Jecho Biopharmaceuticals Co., Ltd. n=443
NCT04690556 COMPLETED
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
Lupin Ltd. n=600
NCT07214740 COMPLETED
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
Apellis Pharmaceuticals, Inc. n=44
NCT05439629 COMPLETED
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Bio-Thera Solutions n=488
NCT04522167 COMPLETED
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Bioeq GmbH n=434
NCT03845582 COMPLETED
Phase 2/3 Study of ALK-001 in Geographic Atrophy
Alkeus Pharmaceuticals, Inc. n=200
NCT04770545 COMPLETED
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. n=792
NCT04777201 COMPLETED
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche n=1,036
NCT04435366 COMPLETED
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
IVERIC bio, Inc. n=448
NCT04270747 COMPLETED
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
Amgen n=576
NCT04423718 COMPLETED
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Bayer n=1,011
NCT04757636 TERMINATED
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
Opthea Limited n=998
NCT03823287 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Hoffmann-La Roche n=671
NCT04757610 TERMINATED
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Opthea Limited n=986
NCT03823300 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Hoffmann-La Roche n=658
NCT05536297 COMPLETED
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Astellas Pharma Global Development, Inc. n=278
NCT02686658 COMPLETED
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
IVERIC bio, Inc. n=286
NCT05989126 COMPLETED
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals n=35
NCT05604989 COMPLETED
Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration
Seoul National University Bundang Hospital n=45
NCT05003245 COMPLETED
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Shanghai Henlius Biotech n=407
NCT03844074 COMPLETED
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc. n=61
NCT04516278 COMPLETED
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=195
NCT03834753 COMPLETED
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc. n=228
NCT06190093 COMPLETED
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc. n=400
NCT02434328 COMPLETED
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
Alcon Research n=1,048
NCT04740671 COMPLETED
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Shanghai Henlius Biotech n=410
NCT04047472 COMPLETED
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals n=397
NCT04264819 COMPLETED
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals n=295
NCT04239027 COMPLETED
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Novartis Pharmaceuticals n=210
NCT04005352 COMPLETED
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Novartis Pharmaceuticals n=734
NCT04597632 COMPLETED
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Novartis Pharmaceuticals n=248
NCT05155293 COMPLETED
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
Alvotech Swiss AG n=413
NCT04049266 TERMINATED
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Kodiak Sciences Inc n=559
NCT04964089 COMPLETED
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Kodiak Sciences Inc n=557
NCT04864834 COMPLETED
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Sandoz n=485
NCT04450329 COMPLETED
A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Samsung Bioepis Co., Ltd. n=449
NCT05126966 WITHDRAWN
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche
NCT03805100 COMPLETED
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
Xbrane Biopharma AB n=582
NCT05569148 COMPLETED
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Hoffmann-La Roche n=35
NCT04480463 COMPLETED
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Sam Chun Dang Pharm. Co. Ltd. n=576
NCT05282004 COMPLETED
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Sandoz n=36
NCT05587062 COMPLETED
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Cinnagen n=168
NCT03710564 TERMINATED
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Novartis Pharmaceuticals n=535
NCT04636853 COMPLETED
CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=20
NCT05161806 COMPLETED
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Sandoz n=30
NCT03677934 COMPLETED
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Hoffmann-La Roche n=415
NCT05345236 COMPLETED
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Qilu Pharmaceutical Co., Ltd. n=366
NCT02611778 COMPLETED
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Bioeq GmbH n=712
NCT04697953 WITHDRAWN
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
Novartis Pharmaceuticals
NCT03577899 TERMINATED
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
Chengdu Kanghong Biotech Co., Ltd. n=1,157
NCT03630952 TERMINATED
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
Chengdu Kanghong Biotech Co., Ltd. n=1,157
NCT02540954 COMPLETED
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Bayer n=336
NCT03150589 COMPLETED
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Samsung Bioepis Co., Ltd. n=705
NCT04857177 COMPLETED
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
Chong Kun Dang Pharmaceutical n=312
NCT03954626 COMPLETED
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals n=14
NCT03386474 COMPLETED
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Novartis Pharmaceuticals n=151
NCT03930641 COMPLETED
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
Novartis Pharmaceuticals n=34
NCT03668054 COMPLETED
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
Laboratorio Elea Phoenix S.A. n=22
NCT02462486 COMPLETED
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Allergan n=949
NCT02462928 COMPLETED
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Allergan n=939
NCT03034772 COMPLETED
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Wills Eye n=52
Data: ClinicalTrials.gov